Results 131 to 140 of about 231,116 (154)

The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review. [PDF]

J Thorac Dis
Yao Z, Sun B, Zhang M, Ge P.
europepmc   +1 more source

Impact of time-of-day and timing interval of neoadjuvant immunotherapy and chemotherapy infusions among patients with operable NSCLC using the inverse probability of treatment weighting method: a dual-center, retrospective study. [PDF]

Front Immunol
Yu XY, Zhai WY, Xia ZZ, Ma K, Zhang BH, Yu X, Lin SC, Guo XT, Zhao ZR, Yu ZT.   +9 more
europepmc   +1 more source

Histogram analysis of diffusion kurtosis imaging for T restaging and predicting complete response of locally advanced rectal cancer following neoadjuvant immunotherapy. [PDF]

Quant Imaging Med Surg
Jin Z, Zhang L, Yang F, Guo Y, Hao N, Liu Y, Chen M, Xu S, Lin Z, Sun P, Zheng N, Zheng C, Zhang T, Li X.   +13 more
europepmc   +1 more source

High intratumoral CD8 positive T cell infiltration associated with pathologic complete response after neoadjuvant immunotherapy in locally advanced colon cancer. [PDF]

Discov Oncol
Okabayashi H, Teraishi F, Sumii R, Okamoto K, Toyokawa T, Omote R, Takahashi R, Utsumi M, Miyaso H, Inagaki M.   +9 more
europepmc   +1 more source

The emerging role of neoadjuvant immunotherapy in locally advanced oral squamous cell carcinoma: progress and challenges. [PDF]

Int J Surg
Zhao TC, Dai YB, Zhou ZH, Huang YY, Zhong LP.   +4 more
europepmc   +1 more source

¹⁸F-FDG PET/CT metabolic parameter to predict pathological complete response and survival after neoadjuvant immunotherapy plus chemoradiotherapy in resectable esophageal squamous cell carcinoma. [PDF]

Cancer Imaging
Yang J, Ma L, Zhao X, Jin P, Meng X, Du W, Wu Z, Jiao W, Yang W.   +8 more
europepmc   +1 more source

Distinct roles of nutritional and inflammatory signatures in predicting pathological response versus long-term survival in locally advanced gastric cancer treated with neoadjuvant immunotherapy. [PDF]

Front Oncol
Dong Y, Qian L, Wang Y, Yuan C, Cui W, Shi Y, Zhu J, Ding X.   +7 more
europepmc   +1 more source

Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence. [PDF]

World J Clin Oncol
Cicerone O, Oliviero B, Mantovani S, Maiocchi L, Ravetta V, Berton F, Corallo S, Vanoli A, Maestri M.   +8 more
europepmc   +1 more source

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience

Cancers, 2021
Across all tumor types, we observe that the role of immunotherapy has increased rapidly. Due to a number of potential advantages, it is considered in neoadjuvant treatment of localized tumors.
Paweł Krawczyk, Izabela Chmielewska, Rodryg Ramlau   +2 more
exaly   +2 more sources

Lung Cancer Surgery after Neoadjuvant Immunotherapy

Cancers, 2021
In early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival.
Dirk Michael Stefani, Martin Stuschke, Martin Schuler   +2 more
exaly   +2 more sources